What is Rapid Pathogen Screening?
Rapid Pathogen Screening is a specialized developer and manufacturer of cost-effective point-of-care diagnostic tests designed to address systemic infectious diseases and promote antibiotic stewardship. The company's flagship innovation, the FebriDx test, serves as a critical tool for clinicians by utilizing a finger-stick blood sample to differentiate between bacterial and viral causes of fever in acute respiratory infections. With a 97% negative predictive value and a 15-minute turnaround time, the platform provides actionable data that enables healthcare providers to triage patients efficiently and reduce the unnecessary prescription of antibiotics. This technology addresses a significant unmet need in modern medicine, where rapid, accurate diagnostics are essential for improving patient outcomes and managing public health resources.
How much funding has Rapid Pathogen Screening raised?
Rapid Pathogen Screening has raised a total of $34.6M across 3 funding rounds:
Unspecified
$6.3M
Debt
$28M
Debt
$350K
Unspecified (2013): $6.3M with participation from Mallitz Investment Group
Debt (2014): $28M led by OrbiMed Advisors, LLC
Debt (2020): $350K supported by PPP
Key Investors in Rapid Pathogen Screening
Mallitz Investment Group
A family office platform based in Sarasota, Florida, that implements institutional discipline in the screening and structuring of debt-oriented investments.
OrbiMed Advisors, LLC
A specialized healthcare investment firm with deep expertise in biopharmaceuticals, medical devices, and diagnostics, supporting companies through various stages of development.
PPP
Public-Private Partnership
What's next for Rapid Pathogen Screening?
With the support of its latest capital injection, Rapid Pathogen Screening is poised to deepen its market penetration and enhance its manufacturing capabilities. The strategic focus will likely center on expanding the clinical utility of the FebriDx platform and navigating the regulatory pathways required for broader international deployment. As the healthcare industry continues to prioritize antibiotic stewardship and efficient triage, the company is well-positioned to leverage its diagnostic expertise to capture additional market share. Future growth will likely involve scaling production to meet rising demand while maintaining the high performance standards that define its current product portfolio. The firm remains a key player in the diagnostic sector, with a clear mandate to integrate its technology into standard clinical workflows globally.
See full Rapid Pathogen Screening company page
